Regorafenib Improves Survival in Treatment-Refractory Colorectal Cancer
the Cancer Therapy Advisor take:
Compared with placebo, regorafenib improved overall survival in patients with treatment-refractory metastatic colorectal cancer, a recent study published online first in the journal The Lancet Oncology has shown.
For the double-blind, placebo-controlled, parallel-group, phase III trial, researchers enrolled 204 Asian patients with progressive metastatic colorectal cancer who had received at least two previous treatment lines or were unable to tolerate standard treatments. Participants were randomly assigned 2:1 to receive oral regorafenib 160mg once daily or placebo on days 1-21 of each 28-day cycle plus best supportive care.
Results showed that after a median follow-up of 7.4 months, median overall survival was 8.8 months (95% CI: 7.3-9.8) in the regorafenib group and 6.3 months (95% CI: 4.8-7.6) in the placebo group (HR = 0.55; 95% CI: 0.40-0.77; one-sided P = 0.00016).
In regard to safety, drug-related adverse events occurred in 97% of participants treated with regorafenib compared with 46% of those treated with placebo. The most common grade 3 or higher adverse events in the regorafenib group were hand-foot skin reaction, hypertension, hyperbilirubinemia, hypophosphatemia, elevated ALT/AST, elevated lipase concentration, and macropapular rash.
The findings suggest that regorafenib is an important treatment for patients with metastatic colorectal cancer whose disease has progressed after standard treatments, which may or may not include targeted treatments.
Compared with placebo, regorafenib improved overall survival in patients with treatment-refractory metastatic colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma